Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Arcturus Therapeutics Ltd (ARCT)

Arcturus Therapeutics Ltd (ARCT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 819,002
  • Shares Outstanding, K 26,932
  • Annual Sales, $ 166,800 K
  • Annual Income, $ -29,730 K
  • 60-Month Beta 2.65
  • Price/Sales 4.95
  • Price/Cash Flow N/A
  • Price/Book 3.30
Trade ARCT with:

Options Overview Details

View History
  • Implied Volatility 55.93% ( -4.16%)
  • Historical Volatility 63.47%
  • IV Percentile 3%
  • IV Rank 5.57%
  • IV High 93.39% on 11/14/23
  • IV Low 53.72% on 12/04/23
  • Put/Call Vol Ratio 2.33
  • Today's Volume 50
  • Volume Avg (30-Day) 125
  • Put/Call OI Ratio 0.77
  • Today's Open Interest 7,271
  • Open Int (30-Day) 7,724

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/24
See More
  • Average Estimate -1.50
  • Number of Estimates 3
  • High Estimate -0.80
  • Low Estimate -2.11
  • Prior Year -1.98
  • Growth Rate Est. (year over year) +24.24%

Price Performance

See More
Period Period Low Period High Performance
1-Month
25.41 +19.68%
on 04/25/24
32.54 -6.56%
on 05/23/24
+3.43 (+12.71%)
since 04/24/24
3-Month
25.41 +19.68%
on 04/25/24
43.81 -30.59%
on 02/27/24
-7.01 (-18.73%)
since 02/23/24
52-Week
17.52 +73.57%
on 11/13/23
43.81 -30.59%
on 02/27/24
+2.18 (+7.72%)
since 05/24/23

Most Recent Stories

More News
Why Shares of Arcturus Therapeutics Dropped on Tuesday

The company saw revenue decline and net losses rise in the second quarter.

ARCT : 30.41 (-2.56%)
Arcturus Therapeutics (ARCT) Q1 Earnings and Revenues Miss Estimates

Arcturus Therapeutics (ARCT) delivered earnings and revenue surprises of -69.86% and 39.86%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

ARCT : 30.41 (-2.56%)
ACET : 1.4900 (-2.61%)
Coherus BioSciences (CHRS) Reports Q1 Loss, Misses Revenue Estimates

Coherus BioSciences (CHRS) delivered earnings and revenue surprises of -22.95% and 36.07%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

CHRS : 1.9100 (-4.98%)
ARCT : 30.41 (-2.56%)
Arcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 9, 2023

Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a global late-stage clinical messenger RNA medicines company focused on the development of infectious disease vaccines...

ARCT : 30.41 (-2.56%)
Why Arcturus Therapeutics Stock Is Soaring Today

Investors liked what they heard in its Q4 update.

ARCT : 30.41 (-2.56%)
Markets Today: Stock Indexes Climb as Tech Strength Buoys Sentiment

Morning Markets March S&P 500 futures (ESM2 3) this morning are up +0.79%, and March Nasdaq 100 E-Mini futures (NQM2 3) are up +0.82%. U.S. stock index futures this morning are moderately higher. Technology...

ESM24 : 5,321.50s (+0.69%)
NQM24 : 18,876.00s (+0.96%)
LULU : 303.01 (+1.09%)
MU : 129.49 (+2.55%)
AMD : 166.36 (+3.70%)
INTC : 30.72 (+2.13%)
NVDA : 1,064.69 (+2.57%)
QCOM : 210.36 (+4.26%)
ARCT : 30.41 (-2.56%)
HIG : 101.28 (+0.63%)
CCL : 15.13 (+2.37%)
NABL : 12.49 (-0.24%)
Stocks Climb Before the Open as Banking Worries Subside, Alibaba Boosts Sentiment

June S&P 500 futures (ESM23) are up +0.91%, and June Nasdaq 100 E-Mini futures (NQM23) are up +0.93% this morning after three major U.S. benchmark indices finished the regular session lower, while U.S....

ESM23 : 4,453.35s (+0.61%)
NQM23 : 15,316.61s (+0.85%)
AMC : 4.84 (+6.37%)
AMZN : 180.75 (-0.17%)
MKC : 72.21 (+0.08%)
BABA : 81.26 (+0.57%)
UBSG.Z.IX : 28.190 (+1.04%)
IFX.D.DX : 38.010 (+0.26%)
LULU : 303.01 (+1.09%)
NABL : 12.49 (-0.24%)
ARCT : 30.41 (-2.56%)
SLGC : 2.10 (-4.55%)
Arcturus Therapeutics (ARCT) Beats Q4 Earnings and Revenue Estimates

Arcturus Therapeutics (ARCT) delivered earnings and revenue surprises of 332.80% and 19.14%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?...

ARCT : 30.41 (-2.56%)
BMRN : 75.52 (-0.50%)
Arcturus Therapeutics Announces Fourth Quarter 2022 Financial Update and Pipeline Progress

Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a global late-stage clinical messenger RNA medicines company focused on the development of infectious disease vaccines...

ARCT : 30.41 (-2.56%)
Immuneering Corporation (IMRX) Soars 16.9%: Is Further Upside Left in the Stock?

Immuneering Corporation (IMRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near...

IMRX : 1.3900 (-2.11%)
ARCT : 30.41 (-2.56%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Buy with a Weakest short term outlook on maintaining the current direction.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Business Summary

Arcturus Therapeutics Ltd. is a preclinical-stage biopharmaceutical company. It focuses on the discovery, development and commercialization of RNA medicines using proprietary lipid-mediated delivery system LUNAR(TM) and UNA Oligomer chemistry technologies. Arcturus Therapeutics Ltd, formerly known as...

See More

Key Turning Points

3rd Resistance Point 32.65
2nd Resistance Point 32.14
1st Resistance Point 31.28
Last Price 30.41
1st Support Level 29.91
2nd Support Level 29.40
3rd Support Level 28.54

See More

52-Week High 43.81
Fibonacci 61.8% 33.77
Fibonacci 50% 30.67
Last Price 30.41
Fibonacci 38.2% 27.56
52-Week Low 17.52

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar